When considering total S-specific MBCs (subsets pooled), patients with IBD treated with anti-TNF exhibited a lower proportion of MBCs expressing IGHG1–4 class-switched BCRs, and, concomitantly, a greater proportion of BCRs expressing IGHM (Figure 5B). Here, TNF is linked to inflammatory bowel disease.